



Materials we can discuss today

- Common Data Model
- Vocabulary
- Analysis use cases
- ETL tips/tricks





OMOP Common Data Model

Patrick Ryan, PhD
Janssen Research and Development
on behalf of OHDSI team
25 March 2014





Observational Medical Outcomes Partnership

OMOP was a public-private partnership established to inform the appropriate use of observational healthcare databases for studying the effects of medical products:

- Conducting methodological research to empirically evaluate the performance of alternative methods on their ability to identify true associations
- Developing tools and capabilities for transforming, characterizing, and analyzing disparate data sources across the health care delivery spectrum
- Establishing a shared resource so that the broader research community can collaboratively advance the science

<http://omop.org>



Introducing OHDSI

- The Observational Health Data Sciences and Informatics (OHDSI) program is a multi-stakeholder, interdisciplinary collaborative to create open-source solutions that bring out the value of observational health data through large-scale analytics
- OHDSI has established an international network of researchers and observational health databases with a central coordinating center housed at Columbia University



OHDSI's mission

To transform medical decision making by creating reliable scientific evidence about disease natural history, healthcare delivery, and the effects of medical interventions through large-scale analysis of observational health databases for population-level estimation and patient-level predictions

<http://ohdsi.org>




Objectives in OMOP Common Data Model development

- One model to accommodate both administrative claims and electronic health records
 - Claims from private and public payers, and captured at point-of-care
 - EHRs from both inpatient and outpatient settings
 - Also used to support registries and longitudinal surveys
 - One model to support collaborative research across data sources both within and outside of US
 - One model that can be manageable for data owners and useful for data users (efficient to put data IN and get data OUT)
 - Enable standardization of structure, content, and analytics focused on specific use cases
-




Evolution of the OMOP Common data model



Drug Safety Surveillance

CER/PCOR

OMOP CDMv4



OMOP CDM now Version 4, following multiple iterations of implementation, testing, modifications, and expansion based on the experiences of the OMOP community who bring on a growing landscape of research use cases.

<http://omop.org/CDM>



Lessons learned about data model

JAMIA



Validation of a common data model for active safety surveillance research

J Marc Overhage, Patrick B Ryan, Christian G Reich, et al.

Data Model Considerations for Clinical Effectiveness Researchers

Michael G. Kahn, MD, PhD,*†‡ Deborah Batson, BS,‡ and Lisa M. Schilling MD, MSPH§

(*Med Care* 2012;50: S60–S67)

CLINICAL INFORMATICS


(*Med Care* 2013;51: S45–S52)

Identifying Appropriate Reference Data Models for Comparative Effectiveness Research (CER) Studies Based on Data from Clinical Information Systems

Omolola I. Ogunyemi, PhD,* Daniella Meeker, PhD,† Hyeon-Eui Kim, RN, MPH, PhD,‡
Naveen Ashish, PhD,§ Seena Farzaneh, BSc,|| and Aziz Boxwala, MD, PhD‡




OMOP Data Community continues to evolve...






One model, multiple use cases





Key concepts within OMOP CDM v4







Standard Variable Name Conventions across CDMv4

- **<entity>_CONCEPT_ID:**
 - Foreign key into the Standard Vocabulary, which serves as the primary basis for all standardized analytics
 - Ex: `CONDITION_CONCEPT_ID = 31967` contains reference value for SNOMED concept of 'Nausea'
- **<entity>_SOURCE_VALUE:**
 - Verbatim information from the source data, typically used in ETL to map to `CONCEPT_ID`, and not to be used by any standard analytics
 - Ex: `CONDITION_SOURCE_VALUE = '787.02'` was the ICD-9 code captured as a diagnosis from the administrative claim
- **<entity>_TYPE_CONCEPT_ID:**
 - Delineates the origin of the source information, standardized within the Vocabulary
 - Ex: `DRUG_TYPE_CONCEPT_ID` can allow analysts to discriminate between 'Pharmacy dispensing' and 'Prescription written'
- **<entity>_ID:**
 - Unique identifiers for key entities, which can serve as foreign keys to establish relationships across entities
 - Ex: `PERSON_ID` uniquely identifies each individual. `VISIT_OCCURRENCE_ID` uniquely identifies a `PERSON` encounter at a point of care.




Person



- Uniquely identifies all individuals with person-level information in all entities
- Captures standardized demographics
- Allows maintenance of current location and primary provider and care site
- PERSON_ID is a foreign key for all person-level information



Observation period




observation_period	
P	observation_period_id
F	person_id
	observation_period_start_date
	observation_period_end_date



- Spans of time where data source has capture of observational data
- One person may have multiple periods if there is interruption in data capture
- For claims databases, this is analogous to 'continuous enrollment' during time with both medical and pharmacy benefits
- For EHR databases with no defined capture, rules may vary



Visit occurrence




visit_occurrence	
P	visit_occurrence_id
F	person_id
	visit_start_date
	visit_end_date
	place_of_service_concept_id
	care_site_id
	place_of_service_source_value

- Unique identifier for each encounter, can be used as foreign key for observations recorded during each visit
- Main classification for place-of-service:
 - Outpatient
 - Inpatient
 - Emergency room
- Outpatient and ER visits are typically completed on the same day (so VISIT_START_DATE = VISIT_END_DATE)
- Inpatient visits are typically admissions/discharges such that VISIT_END_DATE – VISIT_START_DATE = Length of stay



Drug exposure




drug_exposure	
P	drug_exposure_id
F	person_id
	drug_concept_id
	drug_exposure_start_date
	drug_exposure_end_date
	drug_type_concept_id
	stop_reason
	refills
	quantity
	days_supply
	sig
	prescribing_provider_id
	visit_occurrence_id
	relevant_condition_concept_id
	drug_source_value

- Record for each exposure, with associated verbatim information as available
- In claims data, a drug exposure row for each pharmacy dispensing claim AND a row for each procedure on medical claim which is drug administration
- No inferred information in DRUG_EXPOSURE → we will develop standardized approach to derive END_DATE in DRUG_ERA



Drug era




drug_era	
P	drug_era_id
F	person_id
	drug_concept_id
	drug_era_start_date
	drug_era_end_date
	drug_type_concept_id
	drug_exposure_count

- Span of time a person is assumed to be continuously exposed to a specific ingredient
- Fully derived from DRUG_EXPOSURE table, no source data needed
- Drug records aggregated to RxNorm ingredient level
- Standard analytics applied to enforce consistent assumptions around gaps between prescriptions




Illustrating inferences needed within longitudinal pharmacy claims data for one patient

Person Timeline





Condition occurrence




condition_occurrence	
P	condition_occurrence_id
F	person_id
	condition_concept_id
	condition_start_date
	condition_end_date
	condition_type_concept_id
	stop_reason
	associated_provider_id
	visit_occurrence_id
	condition_source_value



- Record for each condition observed in the dataset
- From claims data, there would be one condition occurrence record for each diagnosis code recorded from all medical claims
- Optionally allow linkage to a corresponding visit and associated provider
- VISIT_OCCURRENCE_ID allows linkage to specific CARE_SITE through the VISIT_OCCURRENCE table



Condition era




condition_era	
P	condition_era_id
F	person_id
	condition_concept_id
	condition_era_start_date
	condition_era_end_date
	condition_type_concept_id
	condition_occurrence_count

- Analogous to DRUG_ERA, a derived table to consolidate condition occurrence records into meaningful units for analysis
- Combines diagnosis instances into continuous episodes of care for a given condition
- Standardizes some aspects of data cleaning, but does not replace need to make study-specific choices around disease onset and length of illness



Procedure occurrence




- Record for each medical procedure observed
- In claims data, procedures may be observed on both outpatient claims (CPT, HCPCS) and inpatient claims (ICD9P)

procedure_occurrence	
P	procedure_occurrence_id
F	person_id
	procedure_concept_id
	procedure_date
	procedure_type_concept_id
	associated_provider_id
	visit_occurrence_id
	relevant_condition_concept_id
	procedure_source_value



Observation





observation	
P	observation_id
F	person_id
	observation_concept_id
	observation_date
	observation_time
	value_as_number
	value_as_string
	value_as_concept_id
	unit_concept_id
	range_low
	range_high
	observation_type_concept_id
	associated_provider_id
	visit_occurrence_id
	relevant_condition_concept_id
	observation_source_value
	units_source_value

- “Catch-all” that can accommodate a wide array of other types of clinical observations, such as laboratory values, signs/symptoms, family history, rule-out conditions
- Observation values can be numeric, string, or concept
- Laboratory data requires standardizing CONCEPT (LOINC) and UNIT (UCUM), and values commonly compared with normal range




Provider / Care site / Organization

- Tables to record administration of care, used in system/quality analyses
- Data not available in many sources





Incorporating financial information



drug_cost	
P *	drug_cost_id
F *	drug_exposure_id
	paid_copay
	paid_coinsurance
	paid_toward_deductible
	paid_by_payer
	paid_by_coordination_benefits
	total_out_of_pocket
	total_paid
	ingredient_cost
	dispensing_fee
	average_wholesale_price
	payer plan period id

- Each DRUG_EXPOSURE can have one or more DRUG_COST entries
- Each PROCEDURE_OCCURRENCE can have one or more PROCEDURE_COST entries
- Focus on amount paid, and can be broken down by typically available categories
- Cost records can optionally link to person's payer/plan information, as available



Example queries for many use cases



OMOP CDM Queries

Search this site

INTRODUCTION

PERSON

OBSERVATION PERIOD

CARE SITE

PAYER PLAN PERIOD

CONDITION OCCURRENCE

CONDITION OCCURRENCE COMBINATIONS

CONDITION ERA

DRUG EXPOSURE

DRUG ERA

DRUG COST

OBSERVATION

PROCEDURE OCCURRENCE

PROCEDURE COMBINATIONS

PROCEDURE COST

VISIT OCCURRENCE

PROVIDER

LOCATION

DEATH

Person

The Person table is one of the basic four mandatory dimensions of analysis, and when combined with the Drug Exposure, Condition, Observation, and Procedure entities, presents the framework for active drug surveillance. The source data for the Person table comes from person demographics data that will be de-identified to ensure HIPAA compliance. The extent of these data varies by data source. The Person table attribute values are stored as standard Concept codes mapped to the original (i.e., "raw") source values.

The following Person domain queries are available:

- [PE01: Number of patients in the dataset](#)
- [PE02: Number of patients of specific gender in the dataset](#)
- [PE03: Number of patients grouped by gender](#)
- [PE04: Number of patients grouped by race](#)
- [PE05: Number of patients grouped by ethnicity](#)
- [PE06: Number of patients grouped by year of birth](#)
- [PE07: Number of patients grouped by state of residence](#)
- [PE08: Number of patients grouped by zip code of residence](#)
- [PE09: Number of patients by gender, stratified by year of birth](#)
- [PE10: Number of patients by day stratified by day of birth](#)
- [PE11: Number of patients by month stratified by day of birth](#)
- [PE12: Distribution of year of birth](#)
- [PE13: Count of providers](#)
- [PE14: Count of care sites stratified by providers](#)

<http://cdmqueries.omop.org/>



Other resources

- Video presentations of tutorials on how to query data and conduct basic analyses:
<http://omop.org/2013Symposium>
 - CDM specifications and example ETLs from organizations converting their data to the OMOP CDM:
<http://omop.org/CDM>
 - Vocabulary specifications and release notes:
<http://omop.org/Vocabularies>
 - Publications using the OMOP CDM:
<http://omop.org/PublicationList>
-



Concluding thoughts

- OMOP common data model can accommodate different types of observational healthcare data in one standardized, easy-to-use format
- Many different types of observational analyses can be implemented using the same basic building blocks
- Common data model, linked with OMOP vocabulary, can make your analyses standardized and efficient across a network of databases





Join the journey

Interested in OHDSI?
Questions or comments?

Contact:

ryan@ohdsi.org






OMOP vocabulary

Patrick Ryan, PhD
Janssen Research and Development
on behalf of OHDSI team
25 March 2014






Standardizing to a common data model



- Developed with broad stakeholder input
 - Designed to accommodate disparate types of data (claims and EHRs)
 - Optimized to use case of standardized large-scale analytics
 - Conceived for active medical product surveillance, but extensible for other use cases
 - Applied successfully across OMOP data community
 - **Standards-based, conforming to ONC Meaningful Use Stage 2 recommendations**
- <http://omop.org/CDM>




OMOP Common Vocabulary Model



1. All content: concepts in **concept** table
2. Source codes mapped to concepts in **source_to_concept_map**
3. Direct relationships between concepts listed in **concept_relationship**
4. Multi-step hierarchical relationships pre-processed in **concept_ancestor**



General structure of vocabulary





OMOP Common Vocabulary Model

What it is

- Standardized structure to house existing vocabularies used in the public domain
- Compiled standards from disparate public and private sources
- Built on the shoulders of National Library of Medicine's Unified Medical Language System (UMLS)
- Directed, hierarchical representation to facilitate efficient queries within analysis use cases

What it's not


- OMOP didn't create 'new' vocabularies
- Use of OMOP vocabulary does not 'replace' the source values in your system
- Static dataset – the vocabulary updates regularly to keep up with the continual evolution of the sources
- Finished product – vocabulary maintenance and improvement is ongoing activity that requires community participation and support





The concept Table


All vocabularies
stacked up in one
table



Vocabulary ID/Name



Disease Concepts





Codes from Different Vocabularies all Map to Concept

```
/* ICD-9-CM */
```


```
SELECT * FROM source_to_concept_map WHERE source_code = '427.31';
```

```
/* Read */
```

```
SELECT * FROM source_to_concept_map WHERE source_code = 'G573000';
```

```
/* ICD-10-CM */
```


```
SELECT * FROM source_to_concept_map WHERE source_code = 'I48.0';
```





Why not Use Codes?

Reason #1: Different data use different codes



Administrative Claims

- Conditions: ICD-9-CM
 - Until 2014, when ICD-10-CM becomes CMS billing standard
- Drugs: NDC
 - If you only care about pharmacy dispensing
If the product is administered by physician, then HCPCS, ICD9P, CPT4

- Electronic health records

- Conditions: ICD-9-CM, SNOMED, ICD-10-CM, free text
- Drugs: NDC, Multum, GPI, VA Product, ChargeMaster, free text






Codes Used in the World



- Conditions
 - READ, OXMIS, ICD-9-CM, ICD-10-CM, ICPC, MedDRA, freetext in different languages
- Drugs
 - Multilex, DM+D, ATC, NPI, NDC* (*for different nations), freetext in different languages




Reason #2: Disease Hierarchy






Ancestry Relationships: Higher-Level Relationships





How vocabulary integrates with CDM: Condition occurrence



condition_occurrence	
P	condition_occurrence_id
F	person_id
	condition_concept_id
	condition_start_date
	condition_end_date
	condition_type_concept_id
	stop_reason
	associated_provider_id
	visit_occurrence_id
	condition_source_value

- **CONDITION_SOURCE_VALUE** would contain the code originally found in raw database
 - ex. ICD-9-CM for US administrative claims
- **CONDITION_CONCEPT_ID** would contain concept from standard vocabulary
 - ex. corresponding SNOMED concept that ICD-9-CM mapped to in SOURCE_TO_CONCEPT_MAP
- **CONDITION_TYPE_CONCEPT_ID** would contain concept for provenance of the data
 - ex. primary inpatient diagnosis




Does it Work that Way with Drugs?

- Codes
 - NDC, GPI, Multilex, HCPCS, etc.
- Concepts
 - Drug products (Generic and Brand)
 - Drug ingredients
 - Drug Classes
- Relationships
- Ancestry






Drug Hierarchy






Turning NDCs into something useful





How vocabulary integrates with CDM: Drug exposure




drug_exposure	
P	drug_exposure_id
F	person_id
	drug_concept_id
	drug_exposure_start_date
	drug_exposure_end_date
	drug_type_concept_id
	stop_reason
	refills
	quantity
	days_supply
	sig
	prescribing_provider_id
	visit_occurrence_id
	relevant_condition_concept_id
	drug_source_value

- DRUG_SOURCE_VALUE would contain the code originally found in raw database
 - ex. NDC for US administrative claims
- DRUG_CONCEPT_ID would contain concept from standard vocabulary
 - ex. corresponding RxNorm clinical drug concept that NDC mapped to in SOURCE_TO_CONCEPT_MAP
- DRUG_TYPE_CONCEPT_ID would contain concept for provenance of the data
 - ex. pharmacy dispensing



Procedure vocabularies






Lessons learned on standardized vocabulary



Contents lists available at [SciVerse ScienceDirect](#)

Journal of Biomedical Informatics

journal homepage: www.elsevier.com/locate/yjbin



Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases ☆

Christian Reich ^{a,*}, Patrick B. Ryan ^{a,b,1}, Paul E. Stang ^{a,b,1}, Mitra Rocca ^{c,2}

- SNOMED and MedDRA provide useful standards to harmonize data, with minimal information loss in translation from ICD-9-CM

Health Serv Outcomes Res Method (2013) 13:58–67
DOI 10.1007/s10742-012-0102-1

Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure

Frank J. DeFalco • Patrick B. Ryan • M. Soledad Cepeda

- Use of multiple standardized drug vocabularies can improve the quality of observational analysis



Example queries for many use cases



OMOP Vocabulary Queries

Search this site

Introduction
Glossary

General Queries

Condition Queries

Drug Queries

Procedure Queries

Observation Queries

Drug Queries

The following drug domain queries are available:

- [D01: Find drug concept by concept ID](#)
- [D02: Find drug or class by keyword](#)
- [D03: Find ingredients of a drug](#)
- [D04: Find drugs by ingredient](#)
- [D05: Find generic drugs by ingredient](#)
- [D06: Find branded drugs by ingredient](#)
- [D07: Find single ingredient drugs by ingredient](#)
- [D08: Find drug classes for a drug or ingredient](#)
- [D09: Find drugs by drug class](#)
- [D10: Find ingredient by drug class](#)
- [D11: Find source codes by drug class](#)
- [D12: Find indications for a drug](#)
- [D13: Find indications as condition concepts for a drug](#)
- [D14: Find drugs for an indication](#)
- [D15: Find drugs for an indication provided as condition concepts](#)
- [D16: Find drugs for an indication by indication type](#)
- [D17: Find ingredients for an indication](#)

<http://vocabqueries.omop.org/>



Classification systems to support analyses

- UMLS:
 - <http://www.nlm.nih.gov/research/umls/>
- RxNorm
 - <https://www.nlm.nih.gov/research/umls/rxnorm/>
- WHO Anatomical Therapeutic Chemical (ATC)
 - http://www.whocc.no/atc/structure_and_principles/
- First DataBank Enhanced Therapeutic Classification (ETC)
 - <http://www.fdbhealth.com/fdb-medknowledge-foundations/>
- VA National Drug File Reference Terminology (NDF-RT)
 - <http://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/NDFRT/>
- Generic Product Identifier (GPI)
 - <http://www.medi-span.com/medi-span-electronic-drug-file.aspx>
- VA Classification system
 - <http://www.pbm.va.gov/NationalFormulary.asp>



Other resources

- Video presentations of tutorials on how to query OMOP CDM and vocabulary:
<http://omop.org/2013Symposium>
 - CDM specifications and example ETLs from organizations converting their data to the OMOP CDM:
<http://omop.org/CDM>
 - Vocabulary specifications and release notes:
<http://omop.org/Vocabularies>
 - Publications using the OMOP CDM:
<http://omop.org/PublicationList>
-



Join the journey

Interested in OHDSI?
Questions or comments?

Contact:

ryan@ohdsi.org





OMOP Analysis Use Cases

Patrick Ryan, PhD
Janssen Research and Development
on behalf of OHDSI team
25 March 2014





OMOP Common Data Model is only means to an end


CDM design is driven by analysis use cases:

- Descriptive statistics about disease natural history and health service utilization
- Epidemiology study designs to study the effects of medical products
- Informatics solutions to enable real-time exploration of patient-level data, ex:
 - Standardized reporting
 - Risk identification
 - Clinical trial feasibility assessment






One model, multiple use cases






How standardized analytics work across OHDSI network






Data density across the OMOP community






Standardized Records Over Time





Exploring prevalence of disease: ex: Acute Myocardial Infarction




NQMC referent rates from Canada:
0.25% in 2003/4 decreased to
0.22% in 2008/9

Standardized condition prevalence = 5-yr annualized prevalence
stratified by age and gender, standardized to US Census




Exploring prevalence of disease: ex: Acute Myocardial Infarction





Exploring prevalence of disease: ex: Acute Myocardial Infarction

Changes in prevalence over time may reflect changes in data capture process, coding strategy, and/or shifts in population characteristics






Treemap displays 3 dimensions:

Size of rectangle : Standardized prevalence

Color : 'Prevalence ratio', comparing source prevalence with the overall community average


Hierarchy : Aggregate SNOMED-CT concepts by MedDRA System Organ Class





Exploring clinical patterns in laboratory results


ex: Acute Liver Injury



Katz AJ1, Ryan PB, Racoosin JA, Stang PE. Assessment of case definitions for identifying acute liver injury in large observational databases. Drug Saf. 2013 Aug;36(8):651-61. doi: 10.1007/s40264-013-0060-8.



Patient-level exploration: ex: ACE inhibitor and Angioedema





Dabigatran and Postmarketing Reports of Bleeding

Mary Ross Southworth, Pharm.D., Marsha E. Reichman, Ph.D., and Ellis F. Unger, M.D.

Questions we are regularly asked:

- 1) What does it take to do an analysis like this?
- 2) How can this be done against the OMOP CDM?

	Patients	Events	100,000 days at risk)	Patients	Events	100,000 days at risk)
Gastrointestinal hemorrhage						
Analysis with required diagnosis of atrial fibrillation	10,599	16	1.6	43,541	160	3.5
Sensitivity analysis without required diagnosis of atrial fibrillation	12,195	19	1.6	119,940	338	3.1
Intracranial hemorrhage						
Analysis with required diagnosis of atrial fibrillation	10,587	8	0.8	43,594	109	2.4
Sensitivity analysis without required diagnosis of atrial fibrillation	12,182	10	0.9	120,020	204	1.9

* Patients were included in the cohorts if, in the 183 days before the index dispensing of dabigatran or warfarin, they were enrolled in plans for drug and medical coverage and had been given a diagnosis of atrial fibrillation in any care setting. Patients were excluded from the cohorts if, in the 183 days before the index dispensing, they had a claim for an event of interest in an inpatient or emergency department setting or a claim for dispensing of dabigatran or warfarin. Events were assessed during drug exposure, from inpatient or emergency department settings only.



All uses of warfarin / dabigatran

Patients with atrial fibrillation

Patients with GI Bleed


Full MiniSentinel analysis implemented in OMOP Lab:

- 1 SQL Statement
- 117 lines
- <3 minutes execution

<http://omop.org/2013Symposium>



Studying causal effects of medical products



“What aspects of that association should we especially consider before deciding that the most likely interpretation of it is causation?”

- Strength
- Consistency
- Temporality
- Plausibility
- Experiment
- Coherence
- Biological gradient
- Specificity
- Analogy

by Sir Austin Bradford Hill CBE DSC FRCP(hon) FRS
(Professor Emeritus of Medical Statistics,
University of London)

Amongst the objects of this newly-founded Section of Occupational Medicine are firstly 'to provide a means, not readily afforded elsewhere, whereby physicians and surgeons with a special knowledge of the relationship between sickness and injury and conditions of work may discuss their problems, not only with each other, but also with colleagues in other fields, by holding joint meetings with other Sections of the Society'; and, secondly, 'to make available information about the physical, chemical and psychological hazards of occupation, and in particular about those that are rare or not easily recognized'.

At this first meeting of the Section and before, with however laudable intentions, we set about

observed association to a verdict of causation? Upon what basis should we proceed to do so?

I have no wish, nor the skill, to embark upon a philosophical discussion of the meaning of 'causation'. The 'cause' of illness may be immediate and direct, it may be remote and indirect underlying the observed association. But with the aims of occupational, and almost synonymously preventive, medicine in mind the decisive question is whether the frequency of the undesirable event B will be influenced by a change in the environmental feature A. How such a change exerts that influence may call for a great deal of research. However, before deducing 'causation' and taking action we shall not invariably have to sit around awaiting the results of that research. The whole chain may have to be unravelled or a few links may suffice. It will depend upon circumstances.


Disregarding then any such problem in semantics we have this situation. Our observations reveal an association between two variables

Austin Bradford Hill, “The Environment and Disease: Association or Causation?,” *Proceedings of the Royal Society of Medicine*, 58 (1965), 295-300.



Introducing HOMER

- Health Outcomes and Medical Effectiveness Research (HOMER) system



- Live, interactive evidence exploration system with fully functional implementations of all of the components of Sir Bradford Hill's viewpoints for risk identification and assessment, plus some additional components designed by the OMOP team





HOMER implementation of Hill's viewpoints





Demos of applications built within OHDSI community

- Concept Explorer
- EARS
- PSYCHIC





Join the journey

Interested in OHDSI?
Questions or comments?

Contact:

ryan@ohdsi.org





OMOP CDM Tips/Tricks for ETL design and development

Patrick Ryan, PhD
Janssen Research and Development
on behalf of OHDSI team
25 March 2014





What is the biggest challenge in the area of working across various data sources or with the common data model (CDM)?

- Successful use of an observational data network requires a collaborative, interdisciplinary approach
 - **Local knowledge** of the source data: underlying data capture process and its role in the healthcare system
 - **Clinical understanding** of medical products and disease
 - **Domain expertise** in the analytical use cases: epidemiology, pharmacovigilance, health economics and outcomes research
 - Command of **advanced statistical techniques** for large-scale modeling and exploratory analysis
 - **Informatics experience** with ontology management and leveraging standard terminologies for analysis
 - **Technical/programming skills** to implement design and develop a scalable solution






Recommended steps for effective OMOP CDM ETL design

- ✓ 1. Training on OMOP CDM and Vocabulary
 2. Discuss analysis opportunities (why are we doing this? What do you want to be able to do once CDM is done...)
 3. Evaluate technology requirements/environment
 4. Discuss data dictionary/documentation on raw database
 5. Systematic scan of raw database
 6. Drafting Business Logic
 - table level
 - variable level
 - value level (mapping)
 - capture what's 'lost'
 7. Create data sample to allow initial development
 8. **DON'T START IMPLEMENTING UNTIL DESIGN IS COMPLETE**
-



Design progression of OMOP CDM tables



Derived

Cohort




Lessons learned (the hard way)

- A successful ETL requires a village, don't make one person try to be the hero and do it all themselves
 - Team design
 - Team implementation
 - Team testing
- Document early and often...the more details the better
- Data quality checking is required at every step of the process
- Don't make assumptions about data based on documentation, verify by looking at the data
- Good design and comprehensive specifications should save unnecessary iterations and thrash during implementation
- ETL design/documentation/implementation is a living process, it'll never be done and it can always be better...but don't let the perfect be the enemy of the good





Compatibility across data models through common ETLs





Join the journey

Interested in OHDSI?
Questions or comments?

Contact:

ryan@ohdsi.org

